NEWS

Health Canada’s Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic Partner

Absolute Efficacy of Cell-Based Influenza Vaccines in Children Aged 2 to 18 Years, Impact of COVID-19 on Canadians’ Views of Influenza, Among Data Being Presented

Safeguarding our people and communities remains our top priority.

/CNW/ - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. Marketed as FLUCELVAX® QUAD, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains¹.